All In Biotech

Drug Trial Radar · NCT07235917

A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea

A Phase 2, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

34

Planned (sponsor's estimate)

Start

Mar 11, 2026

Primary completion

Jan 28, 2028

Study completion May 17, 2028

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Nov 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching an experimental drug called mibavademab (also called "study drug"). The study is focused on participants with a condition called Functional Hypothalamic Amenorrhea (FHA). FHA is a condition where a woman stops menstruating because the brain is not sending the correct hormonal signals to the ovaries, which then are not able to cycle and ovulate properly. The aim of the study is to see how well the study drug helps the body make the hormones necessary for ovulation and reproduction, and to assess its safety. The study is looking at several other research questions, including: * Whether the drug helps bone health * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)

Conditions

  • Functional Hypothalamic Amenorrhea
  • FHA

Interventions

  • MibavademabDrug

    Administered per the protocol

  • PlaceboOther

    Administered per the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from the highest serum estradiol observed during a 28-day periodTime frame: Baseline to month 6

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Arensia Exploratory Medicine Clinic

    Phoenix, Arizona · Recruiting

  • Focus Clinical Research

    West Hills, California · Recruiting

  • Yale University School of Medicine

    New Haven, Connecticut · Recruiting

  • Mayo Clinic Florida

    Jacksonville, Florida · Recruiting

  • Oregon Health and Science University (OHSU)

    Portland, Oregon · Recruiting

  • OBGYN Associates of Erie

    Erie, Pennsylvania · Recruiting

  • Penn State Health Milton South Hershey Medical Center

    Hershey, Pennsylvania · Recruiting

  • University of Pittsburgh

    Philadelphia, Pennsylvania · Recruiting

  • Zillan Clinical Research

    Houston, Texas · Withdrawn

  • University of Virginia School of Medicine

    Charlottesville, Virginia · Recruiting

  • Tidewater Clinical Research - Tidewater Physicians for Women

    Norfolk, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.